Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

IRVINE, Calif., June 25, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001.  The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

"There is a significant unmet need for effective and well-tolerated agents in the treatment of both atherosclerosis and lipid modulation," said Thomas W. Gardner, Chairman and Chief Executive Officer of AtheroNova.  "Based on AHRO-001's preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile.  We look forward to assessing AHRO-001 in human trials and are extremely pleased to have met a significant milestone with transitioning into a clinical stage company."

The Phase 1 study is a randomized, double-blind, placebo controlled study that assesses ascending doses of AHRO-001 in healthy adult volunteers.  The program advanced into Phase 1 clinical testing following extensive successful preclinical studies with AHRO-001.

"This is clearly an exciting and transformative time for us," remarked Mark K. Wedel, MD, Chief Medical Officer of AtheroNova.

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AtheroNova has shown positive results in animal models for regression of pl
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... /PRNewswire-iReach/ -- TwinMed, LLC announced today that ... H.Eric Richard, Inc. (collectively "PrimeCare"), a New England based ... Massachusetts and Maine. "This acquisition is ... substantially increase our base of service for Long Term ...
... flu season still active and allergy season on its ... to actively seek their pharmacist,s advice about the proper ... care provider and are available to help the public ... and allergy symptoms. (Logo: http://photos.prnewswire.com/prnh/20100820/APHALOGO-a ) ...
Cached Medicine Technology:Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 2Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 3Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 4
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2
... Aug. 19 Lupin Ltd.,announced today that the Company ... the AeroChamber Plus(R) line of products with,Forest Laboratories, Inc. ... will use its 50 person sales force to promote,the ... Holding Chamber (VHC) device that is,used with metered dose ...
... Private Access Appoints Marc Kirshbaum as President & COO, Former ... Medical Research through its suite of web-based privacy management ... clinical ... Private Access,Inc., a developer of web-based solutions that enable management ...
... LINTHICUM, MD, August 18, 2008Young researchers presented innovative, ... Conference, a collaborative project of the AUA Foundation ... on August 7-9, 2008. The AUA Foundation hosted ... discuss the most cutting-edge research in sexual medicine. ...
... Team Conference on October 23,2008, ALEXANDRIA, Va., ... improving America,s future. A strong advocate for,children and ... advocate and,tireless worker on behalf of important social ... Edwards will be the opening speaker at,the National ...
... Cialis showed benefit without side effects , , TUESDAY, ... the erectile dysfunction drug tadalafil (Cialis) helped relieve lower ... prostates, according to a new study. , More than ... lower urinary tract symptoms, including increased urination frequency and ...
... more wide-spread ... authentication for network access, DALLAS, Aug. 19 To ... two-factor authentication via hardware tokens in order to,protect patient files, ... to deploy to a wider audience and,cumbersome for the medical ...
Cached Medicine News:Health News:Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 3Health News:New research on sexual function 2Health News:Elizabeth Edwards to be Opening Speaker at National Hospice Conference in Dallas 2Health News:ED Drug Relieves Lower Urinary Tract Symptoms 2Health News:Entrust IdentityGuard Enables Georgia-based Hospital Network to Deploy Strong Authentication for Remote Access 2Health News:Entrust IdentityGuard Enables Georgia-based Hospital Network to Deploy Strong Authentication for Remote Access 3
... An ISI technician carefully inspects your equipment ... any and all problems, and provides you with ... may be working within a tight budget so ... the intricate work of repair begins., , ISI ...
... ALT (GPT) powder reagent is intended for ... in serum. , Infinity ALT (GPT) powder ... stability once reconstituted and convenience, but ensures ... The reagent is suitable for manual use ...
... is a fully automated, versatile analyzer ... is increased due to the continuous loading ... A fully graphical user interface provides fast ... use. Konelab analyzers are delivered with full ...
Inquire...
Medicine Products: